ライフサイエンスコーパス: neurokinin

1 mulation of receptors with neurally released neurokinins.

2 ey were significantly less likely to express neurokinins.

3 d activation of the G alpha(q)-coupled human neurokinin 1 (hNK-1) receptor coexpressed with the WT-hN

4 3) receptor antagonist, dexamethasone, and a neurokinin 1 (NK(1)) receptor antagonist.

5 d with selective antagonists of 5-HT(2A) and neurokinin 1 (NK-1) receptors.

6 key step for efficient synthesis of a potent neurokinin 1 (NK1 ) antagonist in 60 % overall yield.

7 s) via seven-transmembrane G protein-coupled neurokinin 1 (NK1) and NK2 receptors.

8 nerve fibers and activation of its receptor neurokinin 1 (NK1) are important effectors in the transm

9 he neuropeptide substance P (SP) and cognate neurokinin 1 (NK1) nociceptor in PC activation and angio

10 substance P (SP) and its principal receptor neurokinin 1 (NK1) play a specific role in the behaviora

11 gic (Sendide) or non-peptidergic (L703, 606) neurokinin 1 (NK1) receptor antagonist in one masseter m

12 Basic and clinical studies suggest that neurokinin 1 (NK1) receptor antagonists have efficacy in

13 Lamina I neurokinin 1 (NK1) receptor expressing (NK1R(+)) dorsal

14 Lamina I and III neurokinin 1 (NK1) receptor expressing (NK1R+) dorsal ho

15 We also looked for evidence of neurokinin 1 (NK1) receptor internalization in the dorsa

16 compared ERK1/2 activation by the wild-type neurokinin 1 (NK1) receptor with a chimeric NK1 receptor

17 m intracellular stores through its preferred neurokinin 1 (NK1) receptor, thus inducing NO production

18 Almost all neurokinin 1 (NK1) receptor-positive neurons in lamina I

19 ensin II type 1a (AT1a), vasopressin V2, and neurokinin 1 (NK1) receptors are seven-transmembrane rec

20 Although neurokinin 1 (NK1) receptors contribute to hyperalgesia,

21 The effect is blocked by preincubation with neurokinin 1 (NK1; L-732138, 10 mum) and NK3 (SB222200,

22 use of the oral combination of netupitant (a neurokinin 1 [NK1] receptor antagonist) and palonosetron

23 The results also showed neurokinin 1 and not neurokinin 2 as the relevant recept

24 E-1) in controlling substance P (SP) and the neurokinin 1 receptor (NK(1)R) in endosomes of myenteric

25 atory cytokines and of the substance P (SP), neurokinin 1 receptor (NK-1R) in the proximal mesenteric

26 e P (SP), a neuropeptide, interacts with the neurokinin 1 receptor (NK-1R) on immune cells to help co

27 Substance P engages the T cell neurokinin 1 receptor (NK-1R) to enhance IFN-gamma produ

28 SP engages neurokinin 1 receptor (NK-1R) to stimulate cells.

29 monocytic/macrophage THP-1 cells express the neurokinin 1 receptor (NK-1R), and that exposure of thes

30 oinflammatory molecule that interacts with a neurokinin 1 receptor (NK-1R), which is on T cells and h

31 fizer), that blocks the binding of SP to the neurokinin 1 receptor (NK-1R).

32 stance P and microinjection of a substance P-neurokinin 1 receptor (NK1-R) antagonist into the NTS at

33 led an increase of the substance P-inducible neurokinin 1 receptor (NK1-R) in the retina of first, th

34 a interaction with its cognate receptor, the neurokinin 1 receptor (NK1-R), is produced by monocyte/m

35 We have investigated the effect of neurokinin 1 receptor (NK1R) agonists on HEK293 cells tr

36 h neurons in laminae III-IV that express the neurokinin 1 receptor (NK1r) and have dendrites that ent

37 ance P (SP) and hemokinin-1 (HK-1), bind the neurokinin 1 receptor (NK1R) and promote stimulatory imm

38 in the pre-Botzinger complex (pre-BotC), the neurokinin 1 receptor (NK1R) and somatostatin (Sst) pept

39 A subset of preBotzinger Complex (preBotC) neurokinin 1 receptor (NK1R) and somatostatin peptide (S

40 Genetic deletion or antagonism of the neurokinin 1 receptor (NK1R) decreases alcohol intake, a

41 Genetic deletion of the neurokinin 1 receptor (NK1R) has been shown to decrease

42 SP) induces endocytosis and recycling of the neurokinin 1 receptor (NK1R) in endothelial cells and sp

43 Genome editing of the neurokinin 1 receptor (NK1R) in the VTA renders morphine

44 d by spinal opiates; however, when they used neurokinin 1 receptor (NK1R) internalization as an indic

45 Two naturally occurring variants of the neurokinin 1 receptor (NK1R) mediate the effects of SP:

46 d the effects of selective activation of the neurokinin 1 receptor (NK1R) on signaling and traffickin

47 stance P (SP) induces the association of the neurokinin 1 receptor (NK1R) with two classes of protein

48 The neurokinin 1 receptor (NK1R), a G protein-coupled recept

49 We investigated the role of the neurokinin 1 receptor (NK1R), a mediator of behavioral s

50 ith those in laminae III-IV that express the neurokinin 1 receptor (NK1r), form a major route through

51 dulator substance P (SP) and its target, the neurokinin 1 receptor (NK1R), in the generation and regu

52 They were strongly neurokinin 1 receptor (NK1R)-ir and were selectively des

53 mina III projection neurons that possess the neurokinin 1 receptor (NK1r).

54 and immunological activity via high-affinity neurokinin 1 receptor (NK1R).

55 nctions by binding with high affinity to the neurokinin 1 receptor (NK1R).

56 s in the nucleus ambiguus also expressed the neurokinin 1 receptor and were labeled retrogradely from

57 VP release from HNS explants, but neither a neurokinin 1 receptor antagonist [L732,138 (N-acetyl-L-t

58 not evident when cells were treated with the neurokinin 1 receptor antagonist aprepitant before SP st

59 sphamide chemotherapy; and the addition of a neurokinin 1 receptor antagonist for adults who receive

60 in wild-type mice, some pretreated with the neurokinin 1 receptor antagonist SR140333.

61 enase inhibitors), pyrilamine, aprepitant (a neurokinin 1 receptor antagonist), or indomethacin with

62 led trials also support an expanded role for neurokinin 1 receptor antagonists in patients who are tr

63 III of the rat spinal cord that express the neurokinin 1 receptor are densely innervated by peptider

64 in, nitric oxide synthase, somatostatin, and neurokinin 1 receptor but not with neuropeptide Y or cal

65 Finally, we show that the neurokinin 1 receptor for substance P is required for SC

66 cetyltransferase, neuropeptide Y, serotonin, neurokinin 1 receptor protein, and somatostatin, was int

67 wn that blocking substance P (SP) binding to neurokinin 1 receptor with spantide I prevents Pseudomon

68 or 2 additional ICC markers (anoctamin-1 and neurokinin 1 receptor).

69 ibition caused endosomal retention of the SP neurokinin 1 receptor, beta-arrestins, and Src, resultin

70 kinins on platelets are mediated through the neurokinin 1 receptor, which may therefore offer a novel

71 n the monosynaptic C fiber input to lamina I neurokinin 1 receptor-expressing neurons (1-10 Hz stimul

72 (5) pAkt and pmTOR are expressed in neurokinin 1 receptor-positive neurons in laminae I-III

73 We found that when dorsal horn neurokinin 1 receptor-positive neurons or descending ser

74 The neurokinin 1 receptors (NK(1)Rs) and substance P (SP) ha

75 xus (ICC-DMP) of the small intestine express neurokinin 1 receptors (NK1R) and internalize these rece

76 rnalization of mu-opioid receptors (MOR) and neurokinin 1 receptors (NK1R) was measured to assess opi

77 MORs are coexpressed with neurokinin 1 receptors (NK1Rs) in several regions of the

78 ble-stained with antibodies against MORs and neurokinin 1 receptors (NK1Rs) using immunofluorescence.

79 We also found that activation of neurokinin 1 receptors led to SOCE and activation of SOC

80 from neurons expressing mu-opioid receptors, neurokinin 1 receptors, and protein kinase C-gamma.

81 giotensin II receptor type 1 and substance P neurokinin 1 receptors.

82 ells, which express a combination of a GPCR (Neurokinin 1) and YC3.6.

83 s the neuropeptide substance P (SP) receptor neurokinin 1-R (NK1-R).

84 ity, brain-penetrant, hydroisoindoline-based neurokinin-1 (NK(1)) receptor antagonist with a long cen

85 as to determine the potential involvement of neurokinin-1 (NK(1)) receptors to active vasodilatation.

86 induced an upregulation of prodynorphin and neurokinin-1 (NK-1) in dorsal horn neurons, which was su

87 Guidelines recommend use of a neurokinin-1 (NK-1) receptor antagonist in conjunction w

88 retreatment of LAD2 cells with two different neurokinin-1 (NK-1) receptor antagonists and siRNA inhib

89 onchoconstriction in young guinea pigs via a neurokinin-1 (NK-1) receptor mechanism at the first cent

90 We also assessed the role of the striatal neurokinin-1 (NK-1) receptor on pre- and post-synaptic M

91 creased during nociception, and SP activates neurokinin-1 (NK-1) receptors in the spinal cord and per

92 xpression of high affinity receptors for SP (Neurokinin-1 (NK-1) receptors) on microglia and shown th

93 Unilateral intranigral infusions of the neurokinin-1 (NK1) antagonist LY306740 (0 and 50 nmol) b

94 Tac1 and neurokinin-1 (NK1) are involved in autocrine stimulation

95 nsistently and significantly attenuated by a neurokinin-1 (NK1) receptor antagonist (SR140333, 3 muM)

96 mission of pain and inflammation through the neurokinin-1 (NK1) receptor, a G protein-coupled recepto

97 with delta selectivity and as antagonist for neurokinin-1 (NK1) receptors were designed and synthesiz

98 possibly suggestive of an internalization of neurokinin-1 (NK1) receptors, which are highly specific

99 er ear; however, its high affinity receptor, neurokinin-1 (NK1), has not been identified and the phys

100 In conclusion, neurokinin-1 and dopamine D1 receptors are required for

101 tifunctional ligands with opioid agonist and neurokinin-1 antagonist activities can be accomplished a

102 In fact, aprepitant - the first neurokinin-1 antagonist approved by the US Food and Drug

103 ervations, the allodynia was unaffected by a neurokinin-1 antagonist.

104 Neurokinin-1 antagonists compete with substance P, an en

105 Neurokinin-1 antagonists have demonstrated superior anti

106 tic stimuli and clinical trials confirm that neurokinin-1 antagonists have significantly higher effic

107 developments involving antiemetics, such as neurokinin-1 antagonists, corticosteroids, dopamine anta

108 In the water hydrogen bond network the neurokinin-1 has a unique Glu residue instead of the hig

109 period as brief as 30s also produced DVs in neurokinin-1 immunoreactive RVM neurons.

110 mmunoexpression of Substance P in week 8 and neurokinin-1 in weeks 8 and 12 in the superficial lamina

111 nalogue, but not significantly by tachykinin neurokinin-1 or neurokinin-2 receptor-selective agonists

112 uman colonic epithelial cells overexpressing neurokinin-1 receptor (NCM460 NK-1R) in response to SP s

113 alternative, nonapoptotic pcd induced by the neurokinin-1 receptor (NK(1)R) activated by its ligand S

114 SP) induces endocytosis and recycling of the neurokinin-1 receptor (NK(1)R).

115 mmation via binding to the G-protein-coupled neurokinin-1 receptor (NK-1R) and release of proinflamma

116 Substance P (SP) and the neurokinin-1 receptor (NK-1R) are involved in the develo

117 The substance P (SP)-preferring receptor neurokinin-1 receptor (NK-1R) has two forms: a full-leng

118 SP acts by stimulating the neurokinin-1 receptor (NK-1R) on T lymphocytes and other

119 We have shown that substance P (SP) and its neurokinin-1 receptor (NK-1R) regulate intestinal angiog

120 Substance P (SP) via its neurokinin-1 receptor (NK-1R) regulates several gastroin

121 the hypothesis that substance P (SP) and the neurokinin-1 receptor (NK-1R), both in vitro and in vivo

122 mmation that had been considered mediated by neurokinin-1 receptor (NK-1R), we sought to determine wh

123 ression of the proinflammatory and mitogenic neurokinin-1 receptor (NK-1R).

124 chloride secretion, and inflammation via the neurokinin-1 receptor (NK-1R).

125 logic pathways, mainly via its high-affinity neurokinin-1 receptor (NK-1R).

126 influences immune cell functions through the neurokinin-1 receptor (NK-1R).

127 t express the SP receptor, also known as the neurokinin-1 receptor (NK-1r).

128 euronal nitric oxide synthase (nNOS) and the neurokinin-1 receptor (NK1) have been proposed to be inv

129 The neurokinin-1 receptor (NK1R) has two naturally occurring

130 (MOR/DOR) and antagonist bioactivity at the neurokinin-1 receptor (NK1R) have been designed and synt

131 In saline- and CFA-treated rats, neurokinin-1 receptor (NK1R) immunoreactivity was locali

132 e present study, we examined the role of the neurokinin-1 receptor (NK1R) in the modulation of respir

133 However, 33% of PPG(+) neurons contain neurokinin-1 receptor (NK1R) in the rVRG (126 +/- 12; n

134 Neurokinin-1 receptor (NK1R) mediates down-regulation of

135 1) are neuropeptides that signal through the neurokinin-1 receptor (NK1R) to promote inflammation.

136 Substance P neuropeptide and its receptor, neurokinin-1 receptor (NK1R), are reported to present on

137 , protease-activated receptor-2 (PAR(2)) and neurokinin-1 receptor (NK1R), results in drastically dif

138 reBotzinger Complex (preBotC) that coexpress neurokinin-1 receptor (NK1R), SST, and sst2a are critica

139 Neurokinin-1 receptor (NK1R)-expressing neurones that ar

140 pidly internalized upon interaction with the neurokinin-1 receptor (NK1R).

141 type 1 immunity through agonistic binding to neurokinin-1 receptor (NK1R).

142 in trigeminal subnucleus caudalis by NMDA or neurokinin-1 receptor activation, and whether inhibition

143 NMDA or the specific neurokinin-1 receptor agonist [Sar(9),Met(O(2))(11)]-SP

144 Intrastriatal infusion of the neurokinin-1 receptor agonist GR-73632 induced striatal

145 Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondanset

146 compound with delta/micro opioid agonist and neurokinin-1 receptor antagonist activities and with a h

147 can be reduced experimentally by intraductal neurokinin-1 receptor antagonist and clinically by use o

148 med a randomized trial of the ability of the neurokinin-1 receptor antagonist aprepitant to reduce sy

149 ogate for stroke volume) was improved in the neurokinin-1 receptor antagonist group during the first

150 E(2) synthesis in the presence of a specific neurokinin-1 receptor antagonist or in cells genetically

151 We aimed to assess the neurokinin-1 receptor antagonist rolapitant, in combinat

152 However, the neurokinin-1 receptor antagonist significantly reduced b

153 vival in cecal ligation and puncture sepsis (neurokinin-1 receptor antagonist survival = 79% vs vehic

154 Neurokinin-1 receptor antagonist treatment did not preve

155 Finally, pretreatment with the neurokinin-1 receptor antagonist WIN 51,708 (5mg/kg, ip)

156 vely, relative to controls and the selective neurokinin-1 receptor antagonist WIN-51,708 attenuated t

157 Oral aprepitant, a neurokinin-1 receptor antagonist, is recommended in comb

158 his paper will review the characteristics of neurokinin-1 receptor antagonists (NK1-RAs) and the new

159 To review the characteristics of neurokinin-1 receptor antagonists and their potential ro

160 Neurokinin-1 receptor antagonists are effective in reduc

161 Neurokinin-1 receptor antagonists are significantly more

162 Newer antiemetic agents (serotonin and neurokinin-1 receptor antagonists) have increased effica

163 ory to 5-HT3 serotonin receptor antagonists, neurokinin-1 receptor antagonists, and dexamethasone.

164 who will benefit most from prophylaxis using neurokinin-1 receptor antagonists.

165 These data show that early activation of the neurokinin-1 receptor by substance P decreases sepsis su

166 eraction of substance P with the substance P neurokinin-1 receptor expressed by a variety of immune c

167 e present study, we assessed the role of the neurokinin-1 receptor in the production of striatal 3-ni

168 The neurokinin-1 receptor is expressed by lamina I projectio

169 Neurokinin-1 receptor mRNA levels in the ipsilateral dor

170 The neurokinin-1 receptor signals efficiently through Gq, Gs

171 Neurokinin-1 receptor treatment at the initiation of sep

172 ent study examined whether inhibition of the neurokinin-1 receptor with a specific antagonist (CJ-12,

173 e formation of DVs by Sub P, implicating the neurokinin-1 receptor, a Gq type of G protein coupled re

174 RVM neurons that were immunoreactive for the neurokinin-1 receptor, but not serotonin.

175 prototypical G protein-coupled receptor, the neurokinin-1 receptor, during its different phases of ce

176 Substance P, the principal ligand for the neurokinin-1 receptor, is a potent proinflammatory media

177 impact of deficiency in SP or its receptor, neurokinin-1 receptor, on wound healing in mouse models.

178 ubstance P peptide, a potent agonist for the neurokinin-1 receptor, with a nitroxide spin probe speci

179 The development of the neurokinin-1 receptor-deficient (NK1R(-/-)) mouse permit

180 e and formed numerous close appositions with neurokinin-1 receptor-ir pre-Botzinger complex neurons.

181 We sought to determine whether there are neurokinin-1 receptor-like-immunoreactive (NK-1R-LI) neu

182 19, the beta(2)-adrenergic receptor, and the neurokinin-1 receptor.

183 Neurokinin-1 receptors (NK1Rs) have been shown to mediat

184 gh-affinity receptors for this neuropeptide (neurokinin-1 receptors [NK-1R]), and we have shown that

185 roduction of NO is modulated by the striatal neurokinin-1 receptors and that this receptor may partic

186 Attaching a single quantum dot to individual neurokinin-1 receptors enabled us to follow with high sp

187 investigating the participation of striatal neurokinin-1 receptors in the methamphetamine (METH)-ind

188 f calcitonin gene-related peptide (CGRP) and neurokinin-1 receptors with CGRP(8-37) and RP67580, resp

189 (SP), acting at 5-HT(2A/2C), 5-HT(4), and/or neurokinin-1 receptors, was required to maintain inspira

190 uctive organs to the brain, and they express neurokinin-1 receptors.

191 ng sites and were prevented by inhibition of neurokinin-1 receptors.

192 te, group I metabotropic glutamate receptor, neurokinin-1, and tyrosine receptor kinase receptors.

193 esent study, we investigated the role of the neurokinin-1, dopamine D1 and D2 receptors on the METH-i

194 ouse HK-1 on the three tachykinin receptors, neurokinin-1-3 (NK1-3).

195 Neurokinin-1-receptor antagonism did not alter pneumonia

196 gimen of ondansetron, dexamethasone, and the neurokinin-1-receptor antagonist casopitant mesylate was

197 Administration of a neurokinin-1-receptor antagonist to block substance P si

198 but was not affected by spantide I. mRNA for neurokinin-1-receptor-1 (NK-1R) was detected in the norm

199 s) in addition to its conventional receptor, neurokinin-1.

200 The results also showed neurokinin 1 and not neurokinin 2 as the relevant receptor.

201 Neurokinin-2 receptor (NK(2)R) binding of [(3)H]-SR48968

202 significantly by tachykinin neurokinin-1 or neurokinin-2 receptor-selective agonists.

203 in-ir (immunoreactive) neurons expressed the neurokinin 3 receptor (NK3R) or nuclear estrogen recepto

204 neurokinin B and its corresponding receptor neurokinin 3 receptor (NK3R).

205 INTERPRETATION: Treatment with a neurokinin 3 receptor antagonist (MLE4901) could be prac

206 trial assessed the effectiveness of an oral neurokinin 3 receptor antagonist (MLE4901) on menopausal

207 agents that have such properties-tachykinin neurokinin 3 receptor antagonists-is proposed as a way o

208 They do not colocalize with the neurokinin 3 receptor that stains a type (or two) of OFF

209 c neuropeptide binding preferentially to the neurokinin 3 receptor.

210 Neurokinin 3 receptors (NK3-Rs) are expressed in the sup

211 agonist LY306740 (0 and 50 nmol) but not the neurokinin-3 (NK3) antagonist SR142801 (0 and 50 nmol) l

212 y neurons by injecting a selective toxin for neurokinin-3 expressing neurons [NK(3)-saporin (SAP)] in

213 ant, two structurally diverse antagonists of neurokinin-3 receptor (NK3), displayed distinct modes of

214 Neurokinin-3 receptor (NK3R) has recently emerged as imp

215 ed that neurokinin B (NKB) and its receptor, neurokinin-3 receptor (NK3R), are essential elements for

216 achykinins or exogenous selective tachykinin neurokinin-3 receptor activation with senktide analogue

217 e were inhibited by the selective tachykinin neurokinin-3 receptor antagonists, SB 223412 or SB 23537

218 disease, although the role of the tachykinin neurokinin-3 receptor has not been elucidated.

219 s mimicked by exogenously applied tachykinin neurokinin-3 receptor-selective agonist, senktide analog

220 These neurons are potentially modulated by neurokinin-3 receptors (NK3Rs) of the tachykinin family

221 onfocal microscopy, we identified tachykinin neurokinin-3 receptors on human bronchial parasympatheti

222 e provide the first evidence that tachykinin neurokinin-3 receptors regulate human bronchial parasymp

223 er of labeled neurons containing Substance P/Neurokinin A (approximately 20% of total labeled neurons

224 f neuropeptides, including substance P (SP), neurokinin A (NKA), and neurokinin B (NKB), that are enc

225 Substance P and neurokinin A bind to the reconstituted receptor in a bip

226 ceptors were able to bind to substance P and neurokinin A ligand with similar affinities; however, th

227 C1 (encoding the tachykinins substance P and neurokinin A) to be strongly activated by LP within the

228 ogues of SP, and the NK-2 endogenous ligand, neurokinin A, and is coupled to the phospholipase C path

229 of neuropeptides including substance P (SP), neurokinin A, and neurokinin B, which are recognized for

230 binding of the three peptides, substance P, neurokinin A, and propionyl[Met(O(2))(11)]SP(7-11), to t

231 , Lys-bradykinin, Lys-(des-Arg9)-bradykinin, neurokinin A, Met-Lys-bradykinin, histatin 8, and a myos

232 Despite its inability to respond to neurokinin A, we found that NK1-betaArr1 expression caus

233 ion and nuclear translocation in response to neurokinin A.

234 gents targeting other receptor sites include neurokinin and neurohormonal modulators, chloride channe

235 ith histamine (pyrilamine or cromolyn), or a neurokinin antagonist (spantide).

236 eceiving highly emetogenic chemotherapy, the neurokinin antagonist aprepitant significantly enhanced

237 itors, opioids, cholecystokinin antagonists, neurokinin-antagonists, chloride channel activators, gua

238 The neurokinins are neuropeptides that elicit their effect t

239 Neurokinin B (NKB) and its G-protein-coupled receptor, N

240 Patients with loss-of-function mutation in neurokinin B (NKB) and its receptor show hypogonadotropi

241 Human genetic studies have revealed that neurokinin B (NKB) and its receptor, neurokinin-3 recept

242 determine whether preprodynorphin (Dyn) and neurokinin B (NKB) are coexpressed in Kiss1 neurons in t

243 Neurokinin B (NKB) is a hypothalamic neuropeptide bindin

244 Kisspeptin (Kiss1) and neurokinin B (NKB) neurocircuits are essential for puber

245 Arcuate neurokinin B (NKB) neurons express estrogen receptor-alp

246 derable evidence suggests that dynorphin and neurokinin B (NKB) neurons in the hypothalamic arcuate n

247 ction mutations in the genes encoding either neurokinin B (NKB) or its receptor, NK3 (NK3R), result i

248 procal plots of identical slope when [MePhe7]neurokinin B (NKB) was used as the other competition par

249 ng substance P (SP), neurokinin A (NKA), and neurokinin B (NKB), that are encoded by the tac1 (SP and

250 conservation and physiological functions of neurokinin B (NKB), we identified tachykinin (tac) and t

251 in receptor (KISS1R, formerly called GPR54), neurokinin B (TAC3), and the neurokinin B receptor (TACR

252 micked by NK1 (substance P, 100 nm) and NK3 (neurokinin B [NKB], 100 nm) agonists.

253 he Tac2 gene, which encodes the neuropeptide neurokinin B and its corresponding receptor neurokinin 3

254 called GPR54), neurokinin B (TAC3), and the neurokinin B receptor (TACR3) result in pubertal failure

255 Neurokinin B signalling is increased in menopausal women

256 thalamic neurons that produce kisspeptin and neurokinin B stimulate GnRH release.

257 cystokinin, pronociceptive Substance P (SP), Neurokinin B, and a late wave of somatostatin.

258 ncluding substance P (SP), neurokinin A, and neurokinin B, which are recognized for their roles in th

259 arked alterations in hypothalamic kisspeptin/neurokinin B/dynorphin (KNDy) neurons, we hypothesized t

260 are also effects at the ARH to disrupt Kiss1/neurokinin B/dynorphin neuronal function through inhibit

261 We demonstrate that a "neuropeptide," neurokinin-B (NK-B), reversibly inhibits endothelial cel

262 hich encodes proneurokinin-B, a precursor of neurokinin-B (NK-B).

263 idromic release of substance P, and of other neurokinins encoded by the preprotachykinin A (PPT-A) ge

264 second fish putative peptide, referred to as neurokinin F (NKF), is unique and found to be conserved

265 Neurokinins function through G protein-coupled transmemb

266 ysis showed that piscine Tac3s and mammalian neurokinin genes arise from one lineage.

267 utamate transporters (VGlut2 and VGlut3) and neurokinin I receptors were found in distinct regions of

268 el pathways specifically activated by either neurokinin I, corticotropin-releasing factor receptor 1,

269 s tachykinin receptor 86C (also known as the neurokinin K receptor of D. melanogaster), now has been

270 tive sensory fibers and hemopoietic cells in neurokinin-mediated inflammation and suggest that such s

271 found a significant peripheral component in neurokinin NK-receptor mediated emesis, the authors unde

272 ce-based targets for antipsychotic agents: a neurokinin (NK(3)) antagonist (SR142801), a serotonin 2A

273 The current experiments examined whether neurokinin (NK) 1 and 2 receptors are involved in the ac

274 Neurokinin (NK) 1 receptors and CaV2.3 calcium channels

275 was designed to test the hypotheses that (1) neurokinin (NK) receptor activity modulates hyperventila

276 SP activates neurokinin (NK) receptors, which excites midbrain dopami

277 e response mediated by the G-protein-coupled neurokinin NK1 receptor and the tyrosine kinase-linked p

278 Results demonstrated that neurokinin (NK1 and NK2) antagonists blocked the inducti

279 ent SAP conjugate to target NTS neurons with neurokinin (NK1) receptors.

280 agonize muscarinic M3, alpha2 adrenergic and neurokinin NK2 receptors, respectively.

281 lanocortin, melatonin, muscarinic M1 and M3, neurokinin, opioid KOP and serotonin receptors.

282 ultiple inflammatory mediators, specifically neurokinins, prostanoids, and histamine.

283 in rat superficial dorsal horn that express neurokinin receptor 1 (NK1), a receptor for substance P,

284 rved following intravenous pretreatment with neurokinin receptor antagonists (3+/-7% relaxations).

285 icular administration (20 nmol h(-1)) of the neurokinin receptor antagonists CP99994 or SB223412.

286 c endothelial cells differentially expressed neurokinin receptor subtypes.

287 gonadotropin-releasing hormone antagonists, neurokinin receptor-1 antagonists), but available inform

288 n the efflux of cAMP from exocrine cells and neurokinin receptors are important in substance P-mediat

289 otein-coupled receptors and the study of the neurokinin receptors in particular.

290 The present experiments examined the role of neurokinin receptors in this learning deficit.

291 Erythroid cells did not express neurokinin receptors, whereas aortic and yolk sac endoth

292 ors (NK1R) was measured to assess opioid and neurokinin release, respectively.

293 suggest that ICC-DMP are primary targets for neurokinins released from enteric motor neurones in the

294 Our study describes a mechanism for neurokinin signaling in sensory neurons and provides evi

295 ate an interaction between the nicotinic and neurokinin signaling systems that may form the basis for

296 pha5-containing nAChRs and depends on intact neurokinin signaling.

297 Here we target the neurokinin system, which is involved in both pain and ad

298 The down-regulation of neurokinin-tachykinin receptors is accomplished by a rap

299 R and DOPR similarly attenuates the DNIC and neurokinin type 1 receptor internalization induced eithe

300 s measured in the spinal cord by visualizing neurokinin type 1 receptor internalization.